Cardiovascular Protective Effects of NP-6A4, a Drug with the FDA Designation for Pediatric Cardiomyopathy, in Female Rats with Obesity and Pre-Diabetes

Cardiovascular Protective Effects of NP-6A4, a Drug with the FDA Designation for Pediatric Cardiomyopathy, in Female Rats with Obesity and Pre-Diabetes

Background: Obese and pre-diabetic women have a higher risk for cardiovascular death than age-matched men with the same symptoms, and there are no effective treatments. We reported that obese and pre-diabetic female Zucker Diabetic Fatty (ZDF-F) rats recapitulate metabolic and cardiac pathology of y...

Full description

Bibliographic Details
Main Authors: Anthony M. Belenchia, Asma Boukhalfa, Vincent G. DeMarco, Alexander Mehm, Abuzar Mahmood, Pei Liu, Yinian Tang, Madhavi P. Gavini, Brian Mooney, Howard H. Chen, Lakshmi Pulakat
Format: Article
Language:English
Published: MDPI AG 2023-05-01
Series:Cells
Subjects:
cardiovascular disease (CVD)
body mass index (BMI)
Angiotensin II receptor AT2 (AT2R)
Zucker diabetic fatty-female (ZDF-F)
Zucker diabetic fatty-male (ZDF-M)
Zucker lean-female (ZL-F)
Online Access:https://www.mdpi.com/2073-4409/12/10/1373

Internet

https://www.mdpi.com/2073-4409/12/10/1373

Similar Items